Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
This study has been completed.
PDL BioPharma, Inc.
Information provided by:
First received: April 22, 2005
Last updated: August 2, 2008
Last verified: August 2008
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||October 2006|
|Estimated Primary Completion Date:||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators.. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Erratum in: Lancet Neurol. 2010 Aug;9(8):759. Wadinger, K [corrected to Wandinger, K].